[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":98},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,51,76],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":30,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100632779","phase-1-a-bridging-study-of-efsubaglutide-alfa-in-healthy-adults-in-brazil-100632779",false,"NCT07518121","A Bridging Study of Efsubaglutide Alfa in Healthy Adults in Brazil","A Randomized, Double-Blind, Placebo-Controlled Bridging Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of Efsubaglutide Alfa in Healthy Adult Participants in Brazil","BRIDGE-BR","Inclusion Criteria:\n\n1. Healthy male or female adults, aged 18-45 years (both inclusive) at the time of signing the informed consent form (ICF).\n2. Body mass index (BMI) between 18-28 kg\u002Fm2 (both inclusive). Male participants must weigh no less than 50 kg, and female participants must weigh no less than 45 kg.\n3. Voluntary participation in this study, as documented by the written signature of two copies of the ICF.\n4. Negative serum pregnancy test for women of childbearing potential (WOCBP) during screening period. WOCBP and fertile male participants with WOCBP partners must use highly effective contraception methods without planning to become pregnant or to donate sperm or eggs throughout this study (from signing the ICF to at least 3 months after completion of this study).\n5. Be able to maintain good communication with the investigators and comply with all requirements of protocol to complete all trial procedures.\n\nExclusion Criteria:\n\n1. Known or suspected allergy to the investigational medicinal product, its components or drugs of the same class, or a clinically significant drug allergy, or a history of atopic allergic disease.\n2. Previously or currently diagnosed diabetes mellitus (T1D or T2D) or prediabetes, according to the diagnostic criteria of the Brazilian Diabetes Society (SBD) guideline, defined by any of the following laboratory findings:\n\n   * FPG ≥126 mg\u002FdL or ≥7.0 mmol\u002FL ;\n   * FPG 100-125 mg\u002FdL or 5.6 -6.9 mmol\u002FL (prediabetes);\n   * HbA1c ≥ 6.5% or ≥48 mmol\u002Fmol;\n   * HbA1c 5.7-6.4% or 39-47 mmol\u002Fmol (prediabetes).\n3. History of clinically significant endocrine disorders that may affect glucose metabolism, body weight, or drug PK, including but not limited to Cushing's syndrome; acromegaly; pheochromocytoma; untreated or uncontrolled thyroid disorders (hyperthyroidism or hypothyroidism); polycystic ovary syndrome (PCOS) with metabolic abnormalities; adrenal insufficiency or other adrenal disorders; pituitary disorders affecting hormonal regulation.\n4. History of acute or chronic pancreatitis, symptomatic gallbladder disease (those who have recovered from cholecystectomy and have no sequelae after treatment are allowable to be enrolled), pancreatic injury or other high-risk factors that may lead to pancreatitis, or screening serum amylase or lipase \\>2X upper limit of normal (ULN).\n5. History of significant gastrointestinal (GI) disorders (e.g., gastroparesis, active ulcers within 6 months, or long-term use of medications that directly affect GI motility, or GI surgery within 6 months prior to screening.\n6. History or presence of hepatic, renal, cardiovascular, neurological, psychiatric, psychological or immunological disorders.\n7. Clinically significant abnormalities in physical examination, vital signs, laboratory tests, or 12-lead ECG at screening, and investigators consider that these abnormalities may affect participant's safety or study results. ECG abnormalities including but not limited to: second- or third-degree atrioventricular block; long QT syndrome or QTcF \\> 450 ms (males) or \\> 470 ms (females). (If the QTcF \\> 450 ms (males) or \\> 470 ms (females), two additional ECG measurements should be repeated, and the mean of the three values should be used to determine the participant's eligibility.); left bundle branch block;Wolff-Parkinson-White syndrome; Or other clinically significant 12-lead ECG abnormalities requiring treatment.\n8. Use of any prescription or over-the-counter (OTC) medications, traditional Chinese medicine within 12 months prior to screening that may confound PK, PD, or safety assessments.\n9. Personal or family history of thyroid C-cell tumors including medullary thyroid carcinoma (MTC), or multiple endocrine neoplasia type 2 (MEN2), or presence of hyperthyroidism or hypothyroidism that has not been controlled with a stable medication dose (defined as a stable dose for at least 3 months or longer).\n10. Positive test results for human immunodeficiency virus (HIV) antibody, hepatitis B surface antigen (HBSAg) and HBV-deoxyribonucleric adic (DNA) ≥ lab-specific ULN (for those with positive result on HBsAg, HBV-DNA test will be performed), hepatitis C antibody (HCV-Ab) and HCV-ribonucleric acid (RNA), participant can be eligible at the discretion of the investigator if HCV-Ab positive and HCV RNA negative, or Treponema pallidum antibody (TP-Ab).\n11. Pregnant or breastfeeding women.\n12. Donation or loss of ≥400 mL of blood within 3 months prior to screening.\n13. History of drug abuse within 1 year prior to screening, or positive drug abuse screening test (including amphetamines (AMP), cocaine (COC), tetrahydrocannabinol (THC), morphine (MOP), benzodiazepines (BZO), and methamphetamines (MET), any one or more of which tested positive).\n14. Consumption of more than 14 units of alcohol per week within 6 months prior to screening (1 unit of alcohol equivalent to 360 mL of beer or 45 mL of spirits with an alcohol content of 40% or 150 mL of wine), or consumption of alcohol-containing products within 48 hours before administration, or positive breath alcohol test before administration.\n15. Participation in other clinical trials of vaccines, medical devices, or other drugs within 12 months prior to screening\n16. Major surgery within 4 weeks prior to screening, or planned major surgery during the study.\n17. Participant with systolic blood pressure (SBP) \\\u003C 90 mmHg or \\> 140 mmHg, or diastolic blood pressure (DBP) \\\u003C 50 mmHg or \\> 90 mmHg after resting in a sitting position, or heart rate (HR) \\\u003C 50 beats per minute (BPM) or \\> 100 bpm at rest in sitting position at the screening.\n18. Any other factors that may affect participation in this study at the discretion of the investigator.",true,"ALL","18 Years","45 Years",{"count":22,"type":23},48,"ESTIMATED","INTERVENTIONAL",[26],"PHASE1","This is a Phase I, randomized, double-blind, placebo-controlled, single-dose study in healthy adult participants in Brazil to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of YN-011. Participants will be randomized to receive a single subcutaneous dose of YN-011 1 mg, YN-011 3 mg, or matching placebo. The study includes screening, approximately 2 days of study-site confinement from the day before dosing to 24 hours after dosing, and outpatient follow-up for 4 weeks. Assessments include safety monitoring, PK blood sampling, PD evaluations, and immunogenicity testing.",[29],"Diabete Type 2",[31,32,33,34,35,36,37],"Efsubaglutide Alfa","Phase 1","Healthy Volunteers","Pharmacokinetics","Brazil","Bridging Study","GLP-1 Receptor Agonist","NOT_YET_RECRUITING","2026-04-01",{"date":41,"type":42},"2026-04-08","ACTUAL",{"date":44,"type":23},"2026-06-01",{"date":46,"type":23},"2026-10-31",{"name":48,"class":49},"Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":24,"phases":61,"briefSummary":63,"conditions":64,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},"100601740","phase-2-the-efficacy-and-safety-of-efsubaglutide-alfa-in-overweightobesitysparkle-100601740","NCT07114419","The Efficacy and Safety of Efsubaglutide Alfa in Overweight\u002FObesity（SPARKLE）","A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Efsubaglutide Alfa Injection in Subjects With Overweight or Obesity","Inclusion Criteria:\n\n1. Willing to comply with protocol required visit schedule and visit requirements and provide written informed consent form (ICF);\n2. Male or female subjects, aged 18 to 75 years (both inclusive) at the time of signing the ICF;\n3. Obese: BMI ≥ 30.0 kg\u002Fm2, with or without comorbidities; Or overweight: 27.0 kg\u002Fm2 ≤ BMI \\\u003C 30.0 kg\u002Fm2, with at least one of the following weight-related comorbidities: pre-diabetes, hypertension, dyslipidemia, fatty liver, osteoarthritis, or obesity-induced obstructive sleep apnea syndrome (If the subject has only fatty liver as a comorbidity, imaging results within the 3 months prior to screening are required for fatty liver);\n4. A self-reported change in body weight less than 5.0% controlled with diet and exercise within 3 months before screening;\n5. Women of childbearing potential (WOCBP) and fertile males with WOCBP partners must use highly effective contraception methods throughout the study (from the signing of ICF to 3 months after the last dose of investigational medicinal products).\n\nExclusion Criteria:\n\n1. Obesity caused by endocrine disease or monogenic mutation, including but not limited to hypothalamic obesity, pituitary obesity, hypothyroidism-related obesity, Cushing's syndrome, insulinoma, acromegaly or hypogonadism;\n2. Known or suspected allergy to the investigational medicinal product, its components or drugs of the same class;\n3. Previously diagnosed diabetes mellitus (including type 1 diabetes mellitus, type 2 diabetes mellitus, diabetes mellitus due to pancreatic damage, or other types of diabetes mellitus \\[except gestational diabetes mellitus\\]);\n4. History of severe gastrointestinal disease (e.g., active ulcers), or gastrointestinal surgery (except for appendectomy, cholecystectomy, or other gastrointestinal endoscopic surgeries deemed by the investigator to have no significant impact on gastrointestinal motility), or clinically significant gastric emptying abnormalities (e.g., pyloric obstruction, gastroparesis), or long-term use of drugs with direct effects on gastrointestinal motility within 6 months before screening, or those who were not suitable for participating in this study at the investigator's discretion;\n5. History of significant cardiovascular or cerebrovascular disease within 6 months before screening, including but not limited to:1) Myocardial infarction, coronary angioplasty or bypass grafting, heart valve disease or heart valve repair, clinically significant arrhythmias requiring treatment, angina, transient ischemic attack, cerebrovascular accident or others; 2)Congestive heart failure classified as Grade III or IV by the New York Heart Association (NYHA) (refer to Appendix 3);\n6. History of acute or chronic pancreatitis, symptomatic gallbladder disease (subjects who have undergone cholecystectomy and have stable condition post-surgery are excluded), or pancreatic injury and other factors that may lead to high risk of pancreatitis;\n7. Presence of hyperthyroidism; or hypothyroidism that has not been controlled with a stable medication dose (defined as a stable dose for 3 months or longer);\n8. Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2);\n9. Subjects who have experienced two or more hypoglycemic events within 6 months prior to screening, defined as blood glucose \\\u003C 2.8 mmol\u002FL (50.4 mg\u002Fdl) or blood glucose not reaching \\\u003C 2.8 mmol\u002FL (50.4 mg\u002Fdl) but with significant hypoglycemia symptoms (manifested by sympathetic arousal \\[e.g., palpitations, anxiety, sweating, dizziness, shaking of the hands, feeling of hunger, etc.\\] and CNS symptoms \\[e.g., altered mentation, cognitive disturbances, seizures and coma\\]);\n10. History of an active or untreated malignancy or are in remission from a clinically significant malignancy (other than basal- or squamous-cell skin cancer, in situ carcinomas of the cervix, or in situ prostate cancer) for less than 5 years; or there is a potential malignancy during screening;\n11. History of severe infection or severe trauma within 3 months prior to screening, or undergoing major surgery or not fully recovering from surgery, and the investigator determines that the participant is unsuitable for this study;\n12. History of significant active or unstable major depressive disorder or other severe psychiatric disorder (for example, schizophrenia, bipolar disorder, or other serious mood or anxiety disorder) within 2 years prior to screening;\n13. Previous suicidal tendency or suicidal behavior;\n14. Suicidal ideation corresponding to type 4 or 5 on the C-SSRS at screening;\n15. PHQ-9 questionnaire ≥ 15 points at screening;\n16. Known active infections, e.g., bacterial, fungal and viral infections, including: 1)Human immunodeficiency virus (HIV) infection: defined as HIV antibody positive; 2)Syphilis infection: defined as treponema pallidum antibody (TP-Ab) positive; 3)Active hepatitis B virus (HBV): defined as hepatitis B surface antigen (HBsAg) positive and HBV-deoxyribonucleic acid (DNA) ≥ lab-specific upper limit of normal (ULN) (for those with positive result on HBsAg, HBV DNA test will be performed and those with positive HBV DNA results will be excluded); 4)Active hepatitis C virus (HCV): defined as HCV antibody (HCV-Ab) positive and HCV-ribonucleic acid (RNA) positive, if HCV-Ab positive and HCV RNA negative can be considered as eligible at the discretion of the Investigator;\n17. Any of the laboratory test results at screening meet the following criteria (if there is a clear reason for re-test, the re-test can be performed once during the screening period, and the investigator should record the reason for re-test): 1)HbA1c ≥ 6.5% or fasting blood glucose ≥ 7.0 mmol\u002FL (126 mg\u002FdL) (fasting blood glucose will be tested at the local laboratory at the time of screening, plasma or serum glucose is acceptable); 2)Thyroid stimulating hormone (TSH) \\> 6.0 mIU\u002FL or \\\u003C 0.4 mIU\u002FL; 3)ALT or AST ≥ 3.0×ULN or total bilirubin (TBIL) ≥ 2× ULN; 4)Fasting TG \\> 5.65 mmol\u002FL (500 mg\u002Fdl); 5)Blood amylase or lipase \\> 2.0×ULN; 6)Calcitonin ≥ 50 ng\u002FL(pg\u002FmL); 7)Estimated glomerular filtration rate (eGFR) ≤ 30 mL\u002Fmin\u002F1.73m2, calculated by the CKD-EPI formula (refer to Appendix 4); 8)International normalized ratio (INR) \\> ULN;\n18. Abnormal 12-lead ECG: second- or third-degree atrioventricular block, long QT syndrome or QTcF \\> 450 ms (males) or \\> 470 ms (females) (refer to Appendix 5), left bundle branch block, Wolff-Parkinson-White syndrome, or other clinically significant abnormalities that require treatment;\n19. Uncontrolled hypertension, defined as systolic blood pressure ≥ 160 mmHg and\u002For diastolic blood pressure ≥ 100 mmHg;\n20. Use of any of the following medications or treatments within 3 months prior to screening: 1)Weight loss drugs, such as semaglutide, sibutramine hydrochloride, orlistat, phentermine, phenylpropanolamine, chlorpheniramine, phentermine, bupropion, lorcaserin, phentermine\u002Ftopiramate mixture, naltrexone\u002Fbupropion mixture, etc.; 2)Chinese herbal medicine, health products, meal replacements affecting body weight; 3)Glucose-lowering drugs, such as metformin, SGLT2 inhibitors, GLP-1R agonists, thiazolidinediones (TZDs), etc; 4)Drugs that may affect body weight, including systemic steroids (Consecutively for 7 or more days), tricyclic antidepressants, psychiatric drugs or sedative drugs (such as imipramine, amitriptyline, mirtazapine, paroxetine, phenelzine, chlorpromazine, thioridazine, clozapine, olanzapine, valproic acid, valproic acid derivatives, lithium salts);\n21. Previous bariatric surgery; acupuncture\u002Fcupping for weight loss, liposuction, and abdominal liposuction within 1 year prior to screening; or plan to undergo corresponding treatment during the study period;\n22. Subjects who have participated in other clinical studies and received investigational drug therapy, vaccines or medical device intervention within 3 months before screening;\n23. Blood donation or blood loss ≥ 400 mL within 3 months before screening, or those who have received blood transfusion;\n24. Inability to be venipunctured and\u002For tolerate venous access;\n25. Alcohol consumption of \\> 21 units per week for males and \\> 14 units per week for females within the 6 months before screening (1 unit=360 mL of beer or 45 mL of spirits with an alcohol content of ≥ 40% or 150 mL of wine);\n26. Have a history or suspected abuse of drug, and the investigator determines that the subject is unsuitable for this study;\n27. Have history of use of marijuana within 3 months before screening and unwillingness to abstain from marijuana use during the study;\n28. Pregnant or lactating women;\n29. Other conditions deemed unsuitable for participation in this study according to the judgment of the investigator..","75 Years",{"count":60,"type":23},200,[62],"PHASE2","This is a multicenter, double-blind, randomized, placebo-controlled phase Ⅱ study to evaluate the efficacy, safety, pharmacokinetics, and immunogenicity of YN-011 in subjects with overweight (27 kg\u002Fm2 ≤ BMI \\\u003C 30 kg\u002Fm2, with at least one comorbidity) or obesity (BMI ≥ 30 kg\u002Fm2, with or without comorbidities). The entire study period will consist of a 2-week screening period, a 22-week double-blind treatment period, and a 4-week off-treatment follow-up period",[65],"Obesity and Overweight","RECRUITING","2025-11-24",{"date":69,"type":42},"2025-12-02",{"date":71,"type":42},"2025-08-25",{"date":73,"type":23},"2026-08-01",{"name":48,"class":49},5,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":58,"enrollmentInfo":83,"targetDuration":4,"studyType":24,"phases":85,"briefSummary":87,"conditions":88,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":4},"100585262","phase-3-efficacy-and-safety-of-efsubaglutide-alfa-injection-3-mg-q2w-in-t2d-patients-100585262","NCT06900075","Efficacy and Safety of Efsubaglutide Alfa Injection 3 Mg Q2W in T2D Patients","Efficacy and Safety of Efsubaglutide Alfa Injection 3 Mg Every Two Weeks in Patients with Type 2 Diabetes: a Multicenter, Randomized, Open-Label Study","Inclusion Criteria:\n\n1. Age between 18 and 75 years (inclusive) at screening, with no restriction on gender;\n2. Diagnosed with Type 2 Diabetes Mellitus (T2DM) according to the 2024 ADA 3.Diabetes Management Standards for at least 8 weeks prior to screening, and no antidiabetic treatment received within the 8 weeks prior to screening;\n\n4.Glycated Hemoglobin (HbA1c) between ≥7.5% and ≤11.0% at screening; 5.Fasting Plasma Glucose (FPG) ≤13.9 mmol\u002FL at screening; 6.Body Mass Index (BMI) between 19.0 and 35.0 kg\u002Fm² (inclusive) at screening; 7.Subjects must be able to understand the purpose and content of the study, willing to receive relevant treatments, voluntarily participate in the study, and provide written informed consent.\n\nExclusion Criteria:\n\n1. Patients with Type 1 diabetes or other specific types of diabetes;\n2. Receipt of any of the following medications or treatments: a. Use of antidiabetic medications (including herbal medicines, other traditional medicines, and health products) within 2 months prior to screening; b. Use of non-antidiabetic medications that may significantly affect glucose metabolism for ≥7 days within 2 months prior to screening \\[e.g., glucocorticoids (excluding inhaled, ophthalmic, or topical applications), growth hormones, sympathomimetic agents (e.g., isoproterenol, dopamine, atropine), high-dose salicylates (e.g., aspirin \\>300 mg\u002Fday), danazol, octreotide, or anabolic androgenic steroids (e.g., oxymetholone, oxandrolone)\\].\n3. Presence of any of the following medical histories or conditions: a. Known hypersensitivity to glucagon-like peptide-1 (GLP-1) receptor agonists; b. History of diabetic ketoacidosis, hyperglycemic hyperosmolar state, or lactic acidosis within 6 months prior to screening; c. Presence of unstable or treatment-requiring proliferative retinopathy or maculopathy, severe diabetic neuropathy, intermittent claudication, or diabetic foot within 6 months prior to screening; d. Severe hypoglycemia (Grade 3) events within 6 months prior to screening, or non-severe hypoglycemia occurring 3 or more times within 1 month prior to screening; e. History of gastroparesis, or clinically significant gastric emptying abnormalities, or severe gastrointestinal diseases as deemed by the investigator; f. Presence of any condition that may cause hemolysis or erythrocyte instability affecting HbA1c measurements (e.g., hematologic malignancies, hemolytic anemia, sickle cell disease); g. History of acute or chronic pancreatitis; h. History of acute cholecystitis within 6 months prior to screening, or symptomatic or treatment-requiring cholelithiasis within 6 months prior to screening (except for subjects who have undergone cholecystectomy and are clinically stable); i. Presence of Cushing's syndrome, hyperthyroidism, or inadequately controlled hypothyroidism at screening (except for subjects who have subclinical hypothyroidism not requiring thyroid hormone therapy as determined by the investigator and with TSH \\\u003C10 mIU\u002Fml); j. History of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma, or a family history of these conditions in a first-degree relative; k. Presence of the following cardiovascular or cerebrovascular conditions within 6 months prior to screening: decompensated heart failure (NYHA Class III or IV), treatment-requiring arrhythmia, unstable angina or myocardial infarction, coronary artery bypass grafting or percutaneous coronary intervention, stroke (ischemic or hemorrhagic), or transient ischemic attack; l. History of malignancy within the past 5 years (excluding clinically cured cervical carcinoma in situ or basal cell carcinoma of the skin) or potential malignancy under evaluation; m. Severe trauma, severe infection, or surgery that may affect glycemic control within 1 month prior to screening, or planned surgery that may interfere with study completion or compliance.\n4. Presence of any of the following conditions at screening or prior to randomization: a. Sitting systolic blood pressure ≥160 mmHg and\u002For diastolic blood pressure ≥100 mmHg; b. Clinically relevant abnormalities on a 12-lead electrocardiogram (ECG) that may affect subject safety or interpretation of study results (e.g., treatment-requiring arrhythmia); c. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\>2.5×ULN, or total bilirubin (TBIL) \\>2.0×ULN; d. Estimated glomerular filtration rate (eGFR) \\\u003C60 mL\u002Fmin\u002F1.73 m² (using CKD-EPI formula); e. Serum calcitonin ≥50 ng\u002FL (pg\u002FmL); f. Hemoglobin \\\u003C100 g\u002FL; g. Fasting triglycerides ≥5.7 mmol\u002FL; h. Serum amylase and\u002For lipase ≥3×ULN.\n5. Presence of the following serological abnormalities at screening: a. Positive HIV antibody; b. Positive hepatitis C antibody (HCV-Ab); c. Positive syphilis-specific antibody; d. Positive hepatitis B surface antigen (HBsAg) and\u002For hepatitis B core antibody (HBcAb); if either test is positive, HBV-DNA quantification must be performed, and subjects with results ≥ the lower limit of detection are excluded from the study.\n6. Receipt of blood or plasma products within 3 months prior to screening, or blood donation or blood loss exceeding 400 mL within 3 months prior to screening.\n7. Known or suspected history of alcohol abuse within the past year \\[defined as a weekly alcohol intake greater than 14 units (1 unit = approximately 360 mL of beer, 45 mL of spirits with 40% alcohol, or 150 mL of wine)\\].\n8. History of drug abuse or substance dependence.\n9. Pregnant or breastfeeding women at screening, or those with a positive pregnancy test.\n10. Subjects of childbearing potential (or female partners of male subjects) who intend to conceive from the time of informed consent signing until 3 months after the last dose, or who are unwilling to use effective contraceptive measures.\n11. Participation in other clinical trials with investigational drugs within 3 months prior to screening.\n12. Any other conditions deemed unsuitable for study participation by the investigator.",{"count":84,"type":23},88,[86],"PHASE3","This study is a multicenter, randomized, open-label, active-controlled clinical trial with a two-period crossover design, aimed at evaluating the efficacy and safety of Efsubaglutide Alfa Injection 3 mg administered Q2W in patients with Type 2 Diabetes Mellitus (T2DM) who have inadequate glycemic control despite dietary and exercise interventions. The primary endpoint is time in range (TIR; glucose concentration 3·9-10·0 mmol\u002FL) during the period from Week 6 to Week 8 of Efsubaglutide Alfa Injection treatment.",[89],"Type 2 Diabetes","2025-03-23",{"date":92,"type":42},"2025-03-28",{"date":94,"type":23},"2025-07-30",{"date":96,"type":23},"2026-03-31",{"name":48,"class":49},""]